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Abstract
Background: In clinical trials, peptides derived from food proteins have shown an effect on blood pressure.
This biological mechanism is mainly due to inhibition of angiotensin-I-converting enzyme (ACE), thereby
regulating blood pressure through the renin-angiotensin system. A meta-analysis of these trials is needed to
better quantify their effect, sources of variation, and possible publication bias.
Objective: To perform a meta-analysis of placebo-controlled clinical trials on peptides derived from food
proteins and their effect on blood pressure.
Design: Trials identified using a defined search strategy in PubMed were included in the meta-analysis, and
their pooled effect was estimated with a random effects model.
Results: Pooled effect of peptides was 5.13 mmHg (95% CI: 7.12, 3.14) for systolic blood pressure,
and 2.42 mmHg (95% CI: 3.82, 1.03) for diastolic blood pressure. There were indications of publi-
cation bias for diastolic blood pressure data.
Conclusions: Peptides derived from food proteins may lead to significantly reduced blood pressure and could
therefore be a supplement or alternative to pharmaceutical treatment for mild hypertension. Their effect
seems more pronounced, or at least comparable, to that of other food components studied by randomized
controlled trials. A high proportion of the reported trials was carried out using the well-known ACE
inhibiting tripeptides  Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP).
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H
igh blood pressure, which is estimated to affect
one-third of the Western population, is an
important risk factor for coronary heart disease,
stroke and renal disease (1). Lifestyle modifications,
including weight loss, quitting smoking, reducing sodium
and alcohol intake, increasing physical activity and
changing diet, are recommended for both treatment and
prevention (2). Besides the recommendation of general
lifestyle changes, efforts have been made to produce
functional foods that contain components  nutraceuti-
cals  which have a blood pressure reducing effect, and
could be a supplement or alternative to the pharmaceu-
tical treatment of hypertension. Bioactive peptides with
angiotensin-I-converting enzyme (ACE) inhibitory and
antihypertensive effects have been the focus of special
attention. They have been isolated from several food
sources, biochemically characterized, and currently, some
commercial food products with clinically proven effects
are used (3). Specifically, milk and dairy products have
been shown to have good effects (4). Results from
extensive randomized, blinded and placebo-controlled
clinical trials are needed to scientifically support claimed
effects. Therefore, it is important to systematically
summarize the findings from such clinical trials on
antihypertensive bioactive peptides derived from foods.
Meta-analysis has been defined as ‘the statistical
analysis of a large collection of analysis results from
individual studies for the purpose of integrating the
finding’ (5). It goes beyond an expert literature review
where the results from various studies are discussed and
compared, since it synthesizes the results of the individual
studies into a new, pooled, result using statistical
methodology (6). This enhances the precision of the
estimates of treatment effects, thereby leading to im-
provement in clinical strategies (7). Even though the
number of expert literature reviews on antihypertensive
peptides from food sources is extensive, to my knowledge
a meta-analysis of placebo-controlled clinical trials has
not been performed. A meta-analysis would contribute to
an improved understanding of the effectiveness of pep-
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DOI: 10.3402/fnr.v52i0.1641tides in hypertension and whether these could be a
feasible supplement to pharmaceutical treatment. The
possible presence of publication bias in these trials was
also investigated.
Methods
Selection of studies
As part of finding a defined search string in PubMed for
relevant clinical trails, literature reviews and selected
clinical trials on bioactive peptides derived from food
proteins were studied. Several searches of databases and
the Internet were also carried out, providing an overview
of the subject. It was also discovered that some reports
have only been published in Japanese. To avoid problems
and limitations with the translation of these reports, it
was decided to perform this meta-analysis solely on trials
published in English. The strategy was to develop a
defined search string that would find all relevant clinical
trials registered in PubMed. The literature reference list
of the selected trials would then be carefully examined to
identify any supplementary trials not registered in
PubMed. The defined search string in PubMed with
generated translations of expressions is shown in Box 1.
By 1 July 2007 it gave 227 hits of which 13 trials were
found relevant for further examination by meta-analysis.
By examining the literature reference list in those trials,
two additional trials were included for meta-analysis
(Fig. 1). Aihara et al. (8) and Mizuno et al. (9) performed
separate studies on patients with high-normal blood
pressure and mild hypertension. Therefore, it was decided
to extract those separate data as independent trials.
Data abstraction
Number, age and sex-ratio of participants, duration of
intervention, baseline systolic (SBP) and diastolic blood
pressure (DBP), change at end of intervention and daily
amount of active component or placebo product were
obtained from each trail (Tables 1 [1022] and 2). In a
trial by Mizuno et al. (9), participants were given
different amounts of active product. Only data from the
group of participants given the highest amount were
abstracted for use in the meta-analysis.
Statistical analysis
The effect of intervention or placebo was not estimated
identically in the trials. This effect was estimated either
with a within or between subject comparison of the
participants’ blood pressure at the start and end of trial
(Table 3). Statistically, let Xij be the blood pressure for the
intervention group, where i1 or 2 which is at start or
end of trial, respectively, and j1, 2,... , n is the
participants with active intervention. Further, let Yij be
the blood pressure for the placebo control group, where
i1 or 2 which is at start or end of trial, respectively, and
j1, 2,... , m is the participants with placebo control.
For within subject comparison, the mean effect of
intervention is defined as
¯ I
1
n
X n
j1
Ij
1
n
X n
j1
(X2jX1j)( 1)
and for placebo
¯ P
1
m
X m
j1
Pj
1
m
X m
j1
(Y2jY1j): (2)
Box 1: Search string in PubMed with generated translations
to ﬁnd clinical trials on effect of peptides derived from food
proteins on blood pressure
Search string in PubMed
(blood pressure OR hypertension)
AND
(clinical trial[ptyp] OR randomized controlled trial[ptyp]
OR clinical trial, phase I[ptyp] OR clinical trial, phase II[ptyp]
OR clinical trial, phase III[ptyp] OR controlled clinical trial[ptyp]
OR placebo)
AND
(beverages OR food OR milk proteins OR vegetables
OR meat OR fishes)
AND
(peptides OR ferment* OR sour OR hydrol*)
Expression Translations in PubMed
Blood pressure ‘‘blood pressure’’[MeSH Terms] OR
(‘‘blood pressure determination’’[TIAB]
NOT Medline[SB]) OR ‘‘blood pressure
determination’’[MeSH Terms] OR blood
pressure[Text Word]
Hypertension ‘‘hypertension’’[MeSH Terms]
OR hypertension[Text Word]
Placebo (‘‘placebos’’[TIAB] NOT Medline[SB])
OR ‘‘placebos’’[MeSH Terms]
OR placebo[Text Word]
Beverages ‘‘beverages’’[MeSH Terms]
OR beverages[Text Word]
Food ‘‘food’’[MeSH Terms] OR food[Text Word]
Milk Proteins ‘‘milk proteins’’[MeSH Terms]
OR milk proteins[Text Word]
Vegetables ‘‘vegetables’’[MeSH Terms]
OR Vegetables[Text Word]
Meat ‘‘meat’’[MeSH Terms] OR meat[Text Word]
Fishes ‘‘fishes’’[MeSH Terms] OR fishes[Text Word]
Peptides ‘‘peptides’’[MeSH Terms]
OR peptides[Text Word]
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intervention is defined as
¯ I
1
n
X n
j1
Ij
1
n
X n
j1
X2j (3)
and for placebo
¯ P
1
m
X m
j1½
Pj
1
m
X m
j1
Y2j: (4)
Estimates of the mean effect of intervention and
placebo with standard deviations (SDI and SDP) were
obtained from the studies. For meta-analysis, the trial
effect for both within subject and between subject
comparisons could then be estimated by
¯ I ¯ P (5)
with standard error of trial effect given by
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n

1
m
s

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(n  1)SD
2
I  (m  1)SD
2
P
(n  m  2)
s
: (6)
Both fixed and random effects models were examined to
calculate the mean pooled effect size with confidence
intervals. The homogeneity among studies was tested
using Cochran’s Q-test (23). In this paper, results
presented are based on a random effects model. To
calculate a pooled effect size, each study was assigned a
weight. The random effects weighted model by DerSi-
monian and Laird (24) based on the inverse variance was
used. Publication bias was visually examined after con-
struction of a funnel plot, where standard error is plotted
against net changes in blood pressure. In addition, Egger
regression and its corresponding test for publication bias
were performed (25). The effect and quality of individual
trials were examined by making cumulative and exclusion
sensitivity forest plots (7). Meta-regression with trial
effects as dependent variable and combined amounts of
tripeptides Valine-Proline-Proline (VPP) and Isoleucine-
Proline-Proline (IPP) in trials as independent variable
weighted by the inverse variance from the random effect
model was performed.
Statistical calculations for meta-analysis and genera-
tion of plots were performed using the MIX software,
version 1.54 (26), andweighted least square regression for
meta-regression was preformed using SPSS 15.0.1 for
Windows (Chicago, IL, USA).
Results
Study characteristics
Characteristics of the included trials for meta-analysis are
given in Tables 1 and 2. A total of 826 participants
completed the trials. In the study by Kawase et al. (12)
DBP was not measured. All trials have been published in
international peer-reviewed journals. Mean duration of
intervention was 7.4 weeks with a minimum intervention
of 4 weeks. More than half of the trials used intervention
with the bioactive peptides IPP and VPP. In most of the
trials, participants were aged more than 50 years on
average, with a higher proportion of males than females.
Quantitative data synthesis
Cochran’s Q-test for homogeneity among studies gave
Q30.52 for SBP data with a p-value of 0.02, and Q
29.10 for DBP data with a p-value of 0.08. This indicated
heterogenicity among the studies, and a random effects
model was used for meta-analysis. Exclusion sensitivity
plots showed that excluding single studies did not affect
pooled results from meta-analysis by more than approxi-
mately 0.5 mmHg (results not shown). The weighted
Placebo-controlled clinical trials on effect by
peptides derived from food proteins on blood
pressure  (n = 13)
Search string in PubMed (Box 1) gave by 1 July
2007: n = 227 publications
Studies not addressing effect
on blood pressure of food
protein derived peptides in
humans (n = 211)
Excluded because blood
pressure monitored after short
time (less than one week)
intervention with bioactive
peptides (n = 2)
Excluded because of non-
English language of paper
(n=1)
Other clinical trials found in
reference list (n=12) of which
nine trials excluded because of
publication in non-English
language (i.e. Japanese) and
one trial because lack of
placebo control
Clinical trials included in meta-analysis (n=15)
Fig. 1. Selection of randomized placebo-controlled trials for
meta-analysis.
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from food proteins was 5.13 mmHg (95% CI: 7.12,
3.14) for SBP (Fig. 2), and 2.42 mmHg (95% CI:
3.82, 1.03) for DBP (Fig. 3). Meta-regression relating
combined amounts per day of IPP and VPP (mg) with
effect on blood pressure was performed, but no statisti-
cally significant effect at the 5% level was found.
Difference between studies with Western or Asian popu-
lation was also examined. Asian studies had a somewhat
larger reduction in blood pressure, but there was no
statistically significant difference at the 5% level. No
statistically significant effect was found for the propor-
tion of males in the studies.
Publication bias
Funnel plots of SBP and DBP (Fig. 4) indicated signs of
publication bias for DBP. This was partly confirmed by
the Egger regression test for publication bias, which gave
p-values of 0.31 and 0.08 for SBP and DBP results,
respectively. There was no indication of repeated pub-
lications of the same trials.
Discussion
Results from the meta-analysis of the clinical trails
showed that peptides derived from food proteins
can significantly reduce SBP and DBP, with pooled
mean effects of 5.13 mmHg (95% CI: 7.12, 3.14)
and 2.42 mmHg (95% CI: 3.82, 1.03), respectively.
There were some signs of heterogeneity and publication
bias among the trials, but exclusion sensitivity analysis
did not indicate that one specific trail had a major impact
on the pooled effect estimate. A high proportion of the
reported trials were carried out using the ACE-inhibiting
tripeptides VPP and IPP.
Onstudyingtheresearchliteratureonbioactivepeptides
derivedfromfoodproteins,itisstrikingthatthenumberof
research papers and literature reviews is extensive com-
pared to the number of controlled clinical trials. Nutra-
ceuticals or functional foods are not subject to the same
strict legislation and documentation requirement using
randomized controlled clinical trials, as is the case for
pharmaceuticals. Much work is based on invitro assays or
to a certain extent animal (rat) experiments. Extensive
searches in other databases, such as the Cochrane Library
or the Internet, did not yield additional English-language
placebo-controlled clinical trials published in peer-
reviewed journals. However, there are some other
trials written in Japanese. Based on official English
translations of abstracts, many of the trials used IPP and
VPP peptides as active components and their effect on
blood pressure was comparable to those reported in this
meta-analysis.
Cochrane’s Q-test indicated heterogenicity among the
studies. The trialswere performed by different groupswith
different active components. The numberof trialswas also
too limited to perform meta-regression to test for many
Table 1. Baseline characteristics of clinical trials included for meta-analysis with mean and standard deviation values
Active intervention Placebo control
Source n SBP (mmHg) DBP (mmHg) Age Male (%) n SBP (mmHg) DBP (mmHg) Age Male (%)
Hata et al. (10) 17 159 (46) 89 (39) 77 (31) 23 13 151 (34) 87 (33) 73 (38) 31
Kawasaki et al. (11) 17 146 (10) 91 (7) 46 (13) 94 12 146 (8) 92 (6) 49 (10) 92
Kawase et al. (12) 10 124 (10) NA NA 100 10 124 (10) NA NA 100
Fujita et al. (13) 30 150 (9) 94 (10) 62 (8) 60 31 149 (7) 93 (9) 61 (10) 58
Seppo et al. (14) 10 148 (13) 94 (6) 49 (6) 30 7 148 (13) 93 (3) 46 (13) 29
Seppo et al. (15) 22 155 (13) 97 (6) 51 (7) 46 17 152 (13) 96 (6) 48 (7) 53
Mizushima et al. (16) 23 148 (10) 95 (10) 44 (10) 100 23 145 (13) 92 (10) 48 (9) 100
Toumilehto et al. (17) 30 153 (10) 98 (7) 51 (10) NA 29 157 (11) 98 (7) 54 (9) NA
Aihara et al.* (8) 20 137 (6) 85 (11) 53 (11) 65 20 137 (5) 85 (5) 50 (12) 65
Aihara et al.** (8) 20 147 (9) 92 (9) 52 (12) 80 20 149 (7) 93 (12) 52 (10) 80
Jauhiainen et al. (18) 53 149 (7) 94 (6) 51 (12) 66.0 55 150 (9) 93 (6) 55 (11) 62
Mizuno et al.* (9) 12 134 (3) 82 (5) NA NA 12 133 (3) 82 (2) NA NA
Mizuno et al.** (9) 21 149 (5) 88.6 (5) NA NA 20 150 (5) 89 (5) NA NA
Sano et al. (19) 72 138 (7) 85 (5) 51 (10) 40.3 72 138 (6) 85 (5) 50 (10) 38.9
Cade ´e et al. (20) 24 138 (12) 87 (10) 56 (11) 25 24 137 (15) 85 (10) 56 (12) 16.7
Lee et al. (21) 27 144 (9) 91 (6) 55 (10) 52 26 141 (12) 90 (6) 48 (12) 62
Pins et al. (22) 15 137 (11) 84 (7) 46 (13) 47 15 135 (9) 82 (6) 47 (14) 47
*Data from participants with high-normal blood pressure.
**Data from participants with mild hypertension.
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4sources of heterogenicity, and the effect of daily intake of
VPP and IPP was not significant. Meta-regression can be
carried out to relate the results of trials to the average
participant’s characteristics, such asbloodpressureor age,
but an interpretation of such results is difficult and should
be carried out with care. This is because the relationship
withparticipantaveragesacrosstrialsmay notbethesame
as the relationship for participants within trials (27).
Therefore, it was not performed in this meta-regression.
Egger regression, funnel plots (Fig. 4) and cumulative
Forrest plots (results not shown) did indicate signs of
publication bias, especially for DBP results. One might
speculate that some studies with low accuracy, e.g. with
few included participants and with little or negative
effects, have not been published in international peer-
reviewed journals. Typically, this could have been minor
research or student projects. Therefore, the random effects
model was used because of the possible presence of
heterogenicity and its appropriateness to test whether a
treatment will have an effect ‘on average’ (28).
Results from this meta-analysis gave a significant
reduction on both SDP and DBP at pB0.01. However,
Table 2. Daily intervention of bioactive components from different food sources and duration of clinical trials included for meta-analysis
Source Daily intervention Active component Food source Placebo
Duration
(weeks)
Hata et al. (10) 100 ml fermented milk 1.5 mg VPP and 1.1 mg IPP
peptide
Milk 100 ml artificially
acidified milk
8
Kawasaki et al.
(11)
100 ml beverage with
hydrolyzed sardine muscle
3 mg VY peptide Fish 100 ml beverage without
hydrolyzed sardine
muscle
4
Kawase et al. (12) 400 ml fermented milk
with whey protein concentrate
Whey protein
concentrate
Milk 400 ml artificially
acidified milk
8
Fujita et al. (13) 10 tablets with active
Katsuobushi oligopeptide
1.5 g Katsuobushi oligopeptide Bonito (fish) 10 tablets with inactive
Katsuobushi powder
5
Seppo et al. (14) 150 ml fermented milk
with strain that increase
production of bioactive peptides
1.5 mg VPP and 1.1 mg IPP
peptide
Milk 150 ml ordinary
fermented milk
8
Seppo et al. (15) 150 ml fermented milk with
process to increase production
of bioactive peptides
2.5 mg VPP and 2.25 mg IPP
peptide
Milk 150 ml ordinary
fermented milk
8
Mizushima et al.
(16)
160 g fermented milk 1.92 mg VPP and 1.15 mg IPP
peptide
Milk 160 g artificially acidified
milk
4
Toumilehto et al.
(17)
150 ml fermented milk with
Lb. helveticus
2.5 mg VPP and 2.5 mg IPP
peptide
Milk 150 ml ordinary
fermented milk
10
Aihara et al. (8) 12 g dried product from
fermented milk
8.3 mg VPP and 4.7 mg IPP
peptide
Milk 12 g dried product made
without fermentation
4
Jauhiainen et al.
(18)
300 ml milk fermented with Lb.
helveticus
30 mg VPP and 22.5 mg IPP
peptide
Milk 300 ml ordinary
fermented milk
10
Mizuno et al. (9) Two tablets of hydrolyzed
casein
3.6 mg of VPPIPP peptide Milk Tablets without
hydrolyzed casein
Sano et al. (19) 200 ml fruit juice with
hydrolyzed casein
1.47 mg VPP and 1.6 mg IPP
peptide
Milk 200 ml fruit juice
without hydrolyzed
casein
12
Cade ´e et al. (20) Tablets containing C12
Peptide (DMV International,
The Netherlands)
3.8 g C12 peptide Milk Placebo tablets 4
Lee et al. (21) 125 ml skimmed milk based
beverage with whey powder
Whey powder Milk 125 ml skimmed milk
based beverage
12
Pins et al. (22) Hydrolyzed whey powder
mixed with water
Hydrolyzed whey powder Milk Unhydrolyzed whey
powder mixed with
water
6
*Data from participants with high-normal blood pressure. **Data from participants with mild hypertension.
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5Table 3. Calculating the effect of trials based on within or between subject comparison of intervention and placebo control treatment
Intervention Placebo control Effect of trial
SBP DBP SBP DBP SBP DBP
Study n Mean SD Mean SD n Mean SD Mean SD Effect SE Effect SE
Within subject comparison of blood pressure
Hata et al. (10) 17 14.1 12.8 6.9 10.3 13 4.4 13.0 2.2 6.9 9.7 4.7 4.7 3.3
Seppo et al. (14) 10 14.9 9.4 8.8 6.8 7 4.1 11.4 2.0 5.2 10.8 5.0 6.9 3.1
Seppo et al. (15) 19 15.4 8.3 9.3 4.8 17 9.4 13.2 5.5 7.4 6.0 3.6 3.8 2.1
Mizushima et al. (16) 23 5.2 11.3 2.0 8.0 23 3.7 10.6 0.3 8.3 1.5 3.2 1.7 2.4
Toumilehto et al. (17) 30 15.8 13.2 10.3 6.5 29 13.5 11.9 9.8 7.5 2.3 3.3 0.5 1.8
Aihara et al.* (8) 20 5.0 8.9 6.0 6.7 20 2.0 8.9 1.0 8.9 3.0 2.8 5.0 2.5
Aihara et al.** (8) 20 10.0 15.7 7.5 15.7 20 0.5 11.2 0.5 8.9 10.5 4.3 7.0 4.0
Jauhianinen et al. (18) 53 5.1 9.4 1.1 5.6 55 3.1 11.5 2.1 6.1 2.0 2.0 1.0 1.1
Cade ´e et al. (20) 24 10.7 7.8 6.9 5.9 24 3.6 11.8 2.7 7.8 7.1 2.9 4.2 2.0
Between subject comparison of blood pressure
Kawasaki et al. (11) 17 137.1 12.0 85.3 8.6 12 142.5 11.5 91.0 8.7 5.4 4.4 5.7 3.2
Kawase et al. (12) 10 118.0 9.5  10 125.0 14.2   7.0 5.4 
Fujita et al. (13) 30 137.5 11.5 86.5 8.2 31 148.5 9.9 92.0 8.4 11.0 2.7 5.5 2.1
Mizuno et al.* (9) 12 131.1 5.8 79.8 6.0 12 133.1 5.5 79.2 4.3 2.0 2.3 0.6 2.1
Mizuno et al.** (9) 21 135.0 10.9 83.9 8.8 20 147.2 10.8 87.3 7.3 12.2 3.4 3.4 2.5
Sano et al. (19) 72 132.3 7.3 81.2 4.8 72 136.4 8.0 83.7 5.6 4.1 1.3 2.5 0.9
Lee et al. (21) 27 143.7 13.5 90.4 6.5 26 137.0 14.4 87.7 6.6 6.7 3.8 2.7 1.8
Pins et al. (22) 15 126.0 6.2 77.0 5.4 15 133.0 7.4 80.0 5.8 7.0 2.5 3.0 2.1
*Data from participants with high-normal blood pressure.
**Data from participants with mild hypertension.
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Fig. 2. Standard forest plot from meta-analysis on systolic
blood pressure. Cochran’s Q-test for homogeneity was Q
30.52, p-value0.02.
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range of 27 mmHg.
Many of the clinical trials were also carried out using
the well-known ACE inhibiting tripeptides, IPP and VPP.
Additional clinical trials on non-specific food protein
hydrolysates could provide a better understanding if the
effect on blood pressure is limited to some specific
peptide structures or is a general property of many
peptides derived from food proteins. Lee et al. (21) was
the only study in which active treatment did not, on
average, reduce blood pressure. They used a hydrolysate,
and the content of specific bioavailable ACE-inhibiting
peptides, such as Valine-Tyrosine (VY), IPP or VPP, was
not identified. That could indicate that the presence of
some specific bioactive peptides is important for clinical
effect, but further investigations are needed to draw such
conclusions. Stratified meta-analysis of trials with or
without tripeptides IPP and VPP gave 4.59 mmHg
(95% CI: 6.61, 2.57) or 5.42 mmHg (95% CI:
10.10, 0.76) for SBP and 2.20 mmHg (95% CI:
3.73, 0.67) or 2.87 mmHg (95% CI: 6.17, 0.44)
for DBP, respectively.
Another interesting result from this stratified meta-
analysis was that the Cochrane Q-test was significant
for trials without VPP and IPP (p0.02 for both SBP
and DBP), but not for trials with IPP and VPP (p0.16
and 0.08 for SBP and DBP, respectively). Bioinformatic
modelling has, for instance, indicated that the pre-
hydrolysis of proteins in foods may influence bioavail-
ability and the ACE-inhibitory effect after digestion (29).
The effect of peptides may also be related to the
association found between protein intake and reduced
blood pressure from meta-analysis of epidemiological
data on dietary protein intake (30). Research on bioactive
peptides is extensive within the dairy field, and most of
the clinical trials used milk-based products (Table 2).
However, lack of controlled clinical trials examining the
effect of different proteins makes it difficult to say if the
original protein source for bioactive peptides is important
for their effect on blood pressure. This area needs further
studies.
Antihypertensive peptides have limitations as pharma-
ceuticals since they are susceptible to degradation by
proteolytic enzymes in the stomach and intestines during
digestion and because of their limited bioavailability (31).
However, compared to other blood pressure reducing
components derived from food sources, bioactive pep-
tides seem to be competitive. For instance, meta-analysis
of fibre supplementation gave a non-significant reduction
of SBP by 1.2 mmHg and a significant 1.5 mmHg
reduction of DBP (32, 33). Recent meta-analyses of
potassium and magnesium supplementation found no
significant effect on blood pressure (34, 35), but is
somewhat contradicted by other previous meta-analyses
(3638). Calcium supplementation has shown to signifi-
cantly effect SBP by 1.86 mmHg (95% CI: 2.91,
0.81) and DBP by 0.99 mmHg (95% CI: 1.61,
0.37) in a meta-analysis by van Mierlo et al. (39), but
this significant effect has been contradicted by Dickinson
et al. (40), who claimed it was due to poor quality,
heterogeneity and biases among trials. For individuals
with elevated blood pressure, a Cochrane review on
salt reduction found a significant reduction in SBP of
5.06 mmHg (95% CI 5.81, 4.31) and DBP of
2.70 mmHg (95% CI 3.16, 2.24). Blood pressure
reduction in individuals with normal blood pressure was
somewhat less (41). In meta-analysis, fish oil supplemen-
tation showed an effect on SBP of 2.1 mmHg (95% CI:
3.2, 1.0) and DBP of 1.6 mmHg (95% CI: 2.2,
1.0) (42). Meta-analysis of clinical trials with garlic
preparations showed a significant reduction in blood
pressure, but the investigators concluded that there was
insufficient evidence to recommend it as a routine clinical
therapy for the treatment of hypertensive subjects (43).
Even though this meta-analysis only showed a limited
effect of peptides derived from food proteins on blood
pressure, it could be an alternative or supplement to
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Fig. 4. Funnel plots of mean effects on systolic and diastolic
blood pressure to detect signs of publication bias.
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7pharmacological treatment in combination with other
lifestyle changes. In more severe hypertension, when a
reduction of  10 mmHg is needed (44), the limited effect
of these bioactive peptides might not provide adequate
treatment. Clinical trials comparing bioactive peptides
with pharmaceuticals are needed to gain better insight
into how effective bioactive peptides could be as an
alternative to medical treatment. The role of food-derived
peptides in diminishing the risk of hypertension remains
to be established.
Conflict of interest and funding
The author has not received any funding or benefits from
industry to conduct this study.
References
1. Kearney P, Whelton M, Reynolds K, Muntner P, Whelton PK,
He J. Global burden of hypertension: analysis of worldwide
data. Lancet 2005; 365: 21723.
2. Krousel-Wood MA, Munther P, He J, Whelton PK. Primary
prevention of essential hypertension. Med Clin North Am 2004;
88: 22338.
3. Yamamoto N, Ejiri M, Mizuno S. Biogenic peptides and their
potential use. Curr Pharm Des 2003; 9: 134555.
4. Lopez-Fandin ˜o R, Otte J, van Camp J. Physiological, chemical
and technological aspects of milk-protein-derived peptides with
antihypertensive and ACE-inhibitory activity. Int Dairy J 2006;
16: 127793.
5. Glass GV. Primary, secondary and meta-analysis of research.
Educ Res 1976; 5(10): 38.
6. Berman NG, Parker RA. Meta-analysis: Neither quick nor easy.
BMC Med Res Methodol 2002; 2: 10.
7. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F.
Methods for meta-analysis in medical research. Chichester, UK:
John Wiley & Sons; 2000.
8. Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y.
Effect of powdered fermented milk with Lactobacillus helveticus
on subjects with high-normal blood pressure or mild hyperten-
sion. J Am Coll Nutr 2005; 24: 25765.
9. Mizuno S, Matsuura K, Gotou T, Nishimura S, Kajimoto O,
Yabune M, et al. Antihypertensive effect of casein hydrolysate in
a placebo-controlled study in subjects with high-normal blood
pressure and mild hypertension. Br J Nutr 2005; 94: 8491.
10. Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y,
Takano T. A placebo-controlled study of the effect of sour milk
on blood pressure in hypertensive subjects. Am J Clin Nutr
1996; 64: 76771.
11. Kawasaki T, Seki E, Osajima K, Yoshida M, Asada K, Matsui
T, et al. Antihypertensive effect of Valyl-Tyrosine, a short chain
peptide derived from sardine muscle hydrolyzate, on mild
hypertensive subjects. J Hum Hypertens 2000; 14: 51923.
12. Kawase M, Hashimoto H, Hosoda M, Morita H, Hosono A.
Effect of administration of fermented milk containing whey
protein concentrate to rats and healthy men on serum lipids and
blood pressure. J Dairy Sci 2000; 83: 25563.
13. Fujita H, Yamagami T, Ohshima K. Effect of an ace-inhibitory
agent, Katsuobushi oligopeptide, in the spontaneously hyper-
tensive rat and in borderline and mildly hypertensive subjects.
Nutr Res 2001; 21: 114958.
14. Seppo L, Kerojoki O, Suomalainen T, Korpela R. The effect of
a Lactobacillus helveticus LBK-16 H fermented milk on
hypertension  a pilot study on humans. Milchwissenschaft
2002; 57: 1247.
15. Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk
high in bioactive peptides has ablood pressure-lowering effect in
hypertensive subjects. Am J Clin Nutr 2003; 77: 32630.
16. Mizushima S, Ohshige K, Watanabe J, Kimura M, Kadowaki T,
Nakamura Y, et al. Randomized controlled trial of sour milk on
blood pressure in borderline hypertensive men. Am J Hypertens
2004; 17: 7016.
17. Tuomilehto J, Lindstro ¨m J, Hyyrynen J, Korpela R, Karhunen
M-L, Mikkola L, et al. Effect of ingesting sour milk fermented
using Lactobacillus helveticus bacteria producing tripeptides on
blood pressure in subjects with milk hypertension. J Hum
Hypertens 2004; 18: 795802.
18. Jauhiainen T, Vapaatalo H, Poussa T, Kyro ¨npalo S, Rasmussen
M, Korpela R. Lactobacillus helveticus fermented milk lowers
blood pressure in hypertensive subjects in 24-h ambulatory
blood pressure measurement. Am J Hypertens 2005; 18: 16005.
19. Sano J, Ohki K, Higuchi T, Aihara K, Mizuno S, Kajimoto O, et
al. Effect of casein hydrolysate, prepared with protease derived
from Aspergillus oryzae, on subjects with high-normal blood
pressure or mild hypertension. J Med Food 2005; 8: 42330.
20. Cade ´e JA, Chang C-Y, Chen C-W, Huang C-N, Chen S-L,
Wang C-K. Bovine casein hydrolysate (C12 peptide) reduces
blood pressure in prehypertensive subjects. Am J Hypertens
2007; 20: 15.
21. Lee Y-M, Skurk T, Hennig M, Hauner H. Effect of a milk drink
supplemented with whey peptides on blood pressure in patients
with mild hypertension. Eur J Nutr 2007; 46: 217.
22. Pins JJ, Keenan JM. Effects of whey peptides on cardiovascular
disease risk factors. J Clin Hypertens 2006; 8: 77582.
23. Cochran WG. The combination of estimates from different
experiments. Biometrics 1954; 10: 10129.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials.
Control Clin Trials 1986; 7: 17788.
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. BMJ 1997;
315: 62934.
26. Bax L, Yu LM, Ikeda N, Tsuruta N, Moons KGM. MIX:
comprehensive free software for meta-analysis of causal resea-
rch data  Version 1.54; 2006 (www.mix-for-meta-analysis.info).
27. Thompson SG, Higgens JPT. How should meta-regression
analysis be undertaken and interpreted? Statist Med 2002; 21:
155973.
28. Petitti DB. Meta-analysis, decision analysis, and cost-effective-
ness analysis. New York, NY: Oxford University Press; 2000.
29. Pripp AH. Initial proteolysis of milk proteins and its effect on
formation of ACE-inhibitory peptides during gastrointestinal
proteolysis: a bioinformatic, in silico, approach. Eur Food Res
Technol 2005; 221: 7126.
30. Liu L, Ikeda K, Sullivan DH, Ling W, Yamori Y. Epidemiolo-
gical evidence of the association between dietary protein intake
and blood pressure: a meta-analysis of published data. Hyper-
tens Res 2002; 25: 68995.
31. Vermeirssen V, van Camp J, Verstraete W. Bioavailability of
angiotensin I converting enzyme inhibitory peptides. Br J Nutr
2004; 92: 35766.
32. Strepple MT, Arends LR, van’t Veer P, Grobbee DE, Geleijnse
JM. Dietary ﬁber and blood pressure: a meta-analysis of
randomized placebo-controlled trials. Arch Intern Med 2005;
165: 1506.
33. Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J.
Effect of dietary ﬁber intake on blood pressure: a meta-analysis
of randomized, controlled clinical trials. J Hypertens 2005; 23:
47581.
Are Hugo Pripp
834. Dickinson HO, Nicolson DJ, Campbell F, Beyer FR, Mason J.
Potassium supplementation for the management of primary
hypertension in adults. Cochrane Database Syst Rev 2006; 19:
CD004641.
35. Dickinson HO, Nicolson DJ, Campbell F, Cook JV, Beyer FR,
Ford GA, et al. Magnesium supplementation for the manage-
ment of essential hypertension in adults. Cochrane Database
Syst Rev 2006; 19: CD004640.
36. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann
D, et al. Effects of oral potassium on blood pressure. Meta-
analysis of randomized controlled clinical trials. JAMA 1997;
277: 162432.
37. Whelton PK, He J. Potassium in preventing and treating high
blood pressure. Semin Nephrol 1999; 19: 4949.
38. Mizushima S, Cappuccio FP, Nichols R, Elliott P. Dietary
magnesium intake and blood pressure: a qualitative overview of
the observational studies. J Hum Hypertens 1998; 12: 44753.
39. van Mierlo LA, Arends LR, Streppel MT, Zeegers MP, Kok FJ,
Grobbee DE, et al. Blood pressure response to calcium
supplementation: a meta-analysis of randomized controlled
trials. J Hum Hypertens 2006; 20: 57180.
40. Dickinson HO, Nicolson DJ, Cook JV, Campbell F, Beyer
FR, Ford GA. et al. Calcium supplementation for the
management of primary hypertension in adults. Cochrane
Database Syst Rev 2006; 19: CD004639
41. He FJ, MacGregor GA. Effect of longer-term modest salt
reduction on blood pressure. Cochrane Database Syst Rev 2004;
CD004937.
42. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ.
Blood pressure response to ﬁsh oil supplementation: metare-
gression analysis of randomized trials. J Hypertens 2002; 20:
14939.
43. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on
blood pressure. J Hypertens 1994; 12: 4638.
44. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green
LA, Izzo JL, et al. Seventh report of the joint national
committee on prevention, detection, evaluation and treatment
of high blood pressure. Hypertension 2003; 42: 120652.
Are Hugo Pripp
Research Services Department, Biostatistics Group, Rikshospitalet,
Sognsvannsveien 20, 0027 Oslo, Norway.
E-mail: are.hugo.pripp@rikshospitalet.no
Effect of peptides on hypertension
9